Evaluation of ATN PD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease

Katheryn A Q Cousins,David J Irwin,Thomas F Tropea,Emma Rhodes,Jeffrey Phillips,Alice S Chen-Plotkin,Michael C Brumm,Christopher S Coffey,Ju Hee Kang,Tanya Simuni,Tatiana M Foroud,Arthur W Toga,Caroline M Tanner,Karl D Kieburtz,Brit Mollenhauer,Douglas Galasko,Samantha Hutten,Daniel Weintraub,Andrew D Siderowf,Kenneth Marek,Kathleen L Poston,Leslie M Shaw,Katheryn A.Q. Cousins,David J. Irwin,Thomas F. Tropea,Alice S. Chen-Plotkin,Michael C. Brumm,Christopher S. Coffey,Tatiana M. Foroud,Arthur W. Toga,Caroline M. Tanner,Karl D. Kieburtz,Andrew D. Siderowf,Kathleen L. Poston,Leslie M. Shaw,
DOI: https://doi.org/10.1212/wnl.0000000000208033
IF: 9.9
2024-02-01
Neurology
Abstract:BACKGROUND AND OBJECTIVES: In Parkinson disease (PD), Alzheimer disease (AD) copathology is common and clinically relevant. However, the longitudinal progression of AD CSF biomarkers-β-amyloid 1-42 (Aβ<sub>42</sub>), phosphorylated tau 181 (p-tau<sub>181</sub>), and total tau (t-tau)-in PD is poorly understood and may be distinct from clinical AD. Moreover, it is unclear whether CSF p-tau<sub>181</sub> and serum neurofilament light (NfL) have added prognostic utility in PD, when combined with CSF Aβ<sub>42</sub>. First, we describe longitudinal trajectories of biofluid markers in PD. Second, we modified the AD β-amyloid/tau/neurodegeneration (ATN) framework for application in PD (ATN<sub>PD</sub>) using CSF Aβ<sub>42</sub> (A), p-tau<sub>181</sub> (T), and serum NfL (N) and tested ATN<sub>PD</sub> prediction of longitudinal cognitive decline in PD.METHODS: Participants were selected from the Parkinson's Progression Markers Initiative cohort, clinically diagnosed with sporadic PD or as controls, and followed up annually for 5 years. Linear mixed-effects models (LMEMs) tested the interaction of diagnosis with longitudinal trajectories of analytes (log transformed, false discovery rate [FDR] corrected). In patients with PD, LMEMs tested how baseline ATN<sub>PD</sub> status (AD [A+T+N±] vs not) predicted clinical outcomes, including Montreal Cognitive Assessment (MoCA; rank transformed, FDR corrected).RESULTS: Participants were 364 patients with PD and 168 controls, with comparable baseline mean (±SD) age (patients with PD = 62 ± 10 years; controls = 61 ± 11 years]; Mann-Whitney Wilcoxon: <i>p</i> = 0.4) and sex distribution (patients with PD = 231 male individuals [63%]; controls = 107 male individuals [64%]; χ<sup>2</sup>: <i>p</i> = 1). Patients with PD had overall lower CSF p-tau<sub>181</sub> (β = -0.16, 95% CI -0.23 to -0.092, <i>p</i> = 2.2e-05) and t-tau than controls (β = -0.13, 95% CI -0.19 to -0.065, <i>p</i> = 4e-04), but not Aβ<sub>42</sub> (<i>p</i> = 0.061) or NfL (<i>p</i> = 0.32). Over time, patients with PD had greater increases in serum NfL than controls (β = 0.035, 95% CI 0.022 to 0.048, <i>p</i> = 9.8e-07); slopes of patients with PD did not differ from those of controls for CSF Aβ<sub>42</sub> (<i>p</i> = 0.18), p-tau<sub>181</sub> (<i>p</i> = 1), or t-tau (<i>p</i> = 0.96). Using ATN<sub>PD</sub>, PD classified as A+T+N± (n = 32; 9%) had worse cognitive decline on global MoCA (β = -73, 95% CI -110 to -37, <i>p</i> = 0.00077) than all other ATN<sub>PD</sub> statuses including A+ alone (A+T-N-; n = 75; 21%).DISCUSSION: In patients with early PD, CSF p-tau<sub>181</sub> and t-tau were low compared with those in controls and did not increase over 5 years of follow-up. Our study shows that classification using modified ATN<sub>PD</sub> (incorporating CSF Aβ<sub>42</sub>, CSF p-tau<sub>181</sub>, and serum NfL) can identify biologically relevant subgroups of PD to improve prediction of cognitive decline in early PD.
clinical neurology
What problem does this paper attempt to address?